USE OF PYRUVATE FOR RETARDING NEUTROPHIL INFILTRATION AND MORPHOLOGIC LOSS IN ISCHEMIC BOWEL

摘要

Treating mammals having ischemic bowel with a therapeutic quantity of pyruvate enterally or parenterally will retard neutrophil infiltration and retain morphology during and following the bowel ischemia. The pyruvate is introduced into the patient enterally or parenterally during the bowel ischemia or the succeeding bowel reperfusion and, preferably, prior to the bowel ischemia. The pyruvate dosage is from 1 % to 20 % by weight of the patient's caloric intake.